Cellestia Biotech Company

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistantcancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.
Technology: Prevention
Industry: Gene Therapy
Headquarters: Basel
Founded Date: 2014
Employees Number: 1-10
Funding Status: Early Stage Venture

Visit Website
info@cellestiabiotech.com
https://twitter.com/cellestiabio
Register and Claim Ownership